Xencor Inc
Company Profile
Business description
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Contact
465 North Halstead Street
Suite 200
PasadenaCA91107
USAT: +1 626 305-5900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
260
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.70 | 47.40 | -0.53% |
| CAC 40 | 8,202.08 | 97.34 | -1.17% |
| DAX 40 | 24,663.61 | 255.08 | -1.02% |
| Dow JONES (US) | 49,596.97 | 313.62 | -0.63% |
| FTSE 100 | 10,276.95 | 161.71 | -1.55% |
| HKSE | 26,335.94 | 290.34 | -1.09% |
| NASDAQ | 25,806.20 | 32.75 | -0.13% |
| Nikkei 225 | 62,431.90 | 401.94 | -0.64% |
| NZX 50 Index | 13,189.87 | 80.74 | -0.61% |
| S&P 500 | 7,337.11 | 28.01 | -0.38% |
| S&P/ASX 200 | 8,730.30 | 50.50 | -0.58% |
| SSE Composite Index | 4,162.27 | 17.82 | -0.43% |